Results 31 to 40 of about 964 (170)

Inhalable Nano Formulation of Cabazitaxel: A Comparative Study with Intravenous Route

Macromolecular Bioscience, Volume 25, Issue 5, May 2025.
Nano drug formulation shows no signs of toxicity for IV and INH routes, whereas higher systemic toxicity occurs in free drug formulation in both. Inhalable nano formulation provides higher and longer retention in deep lung regions due to its size and defies rapid systemic absorption in the lungs.
Elif Kaga, Sadik Kaga, Korhan Altunbas, Nurullah Okumus   +3 more
wiley   +1 more source

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD – focus on olodaterol

Therapeutics and Clinical Risk Management, 2015
Maria Gabriella Matera,1 Josuel Ora,2 Mario Cazzola2,3 1Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, 2Division of Respiratory Medicine, University Hospital Tor Vergata, 3Department of Systems Medicine ...
Matera MG, Ora J, Cazzola M
doaj  

No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD

International Journal of COPD, 2020
Stefan Andreas,1,2 Ulrich Bothner,3 Alberto de la Hoz,3 Isabel Kloer,3 Matthias Trampisch,3 Peter Alter4 1Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen ...
Andreas S, Bothner U, de la Hoz A, Kloer I, Trampisch M, Alter P   +5 more
doaj  

Implication of Central β2 Adrenergic Receptor for the Development of Novel Drugs Against Alzheimer's Disease

Archiv der Pharmazie, Volume 358, Issue 4, April 2025.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive onset of symptoms, including memory loss, accompanied by other neurological impairments. This progression is attributed to the deterioration of neuronal connections and a decrease in neurotransmission.
Alice Wang, Marc Since, Patrick Dallemagne, Christophe Rochais   +3 more
wiley   +1 more source

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results

International Journal of COPD, 2019
Martine Hoogendoorn,1 Isaac Corro Ramos,1 Michael Baldwin,2 Laura Luciani,3 Cecile Fabron,4 Bruno Detournay,4 Maureen PMH Rutten-van Mölken1,5 1institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, the ...
Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH   +6 more
doaj  

β2‐Adrenergic Receptor Agonists in Diabetic Kidney Disease: Exploring a New Frontier

Biochemistry Research International, Volume 2025, Issue 1, 2025.
Diabetic kidney disease is a major cause of end‐stage kidney disease. Various metabolic, hemodynamic, inflammatory, and profibrotic factors secondary to diabetes mellitus result in complex intracellular signaling, which in turn is responsible for the functional and structural changes associated with diabetic kidney disease. The beneficial effects of β2‐
Shreya Hegde, Bharti Chogtu, Rahul Magazine, Ravindra Prabhu, Harleen Khatra   +4 more
wiley   +1 more source

EFFICACY OF COMBINATION OF TIOTROPIUM/OLODATEROL IN PATIENTS WITH COPD IN REAL CLINICAL PRACTICE

Wiadomości Lekarskie, 2022
The aim: Show the efficacy of the Tiotropium / olodaterol combination in real clinical practice. Materials and methods: 100 patients with the diagnosis of COPD were included onto the study during the period of 2019-2020, an average age was 64.09±1.94 years, 66 were men (66 %) and 34 were women (34 %).
Kostiantyn D, Dmytriiev, Yuriy M, Mostovoy, Oleksandr, Dobrovanov, Nataliia S, Slepchenko   +3 more
openaire   +2 more sources

Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat fixed-dose combination for chronic obstructive pulmonary disease patients in Italy

Therapeutic Advances in Respiratory Disease, 2016
Background: The objective of this study was to compare the cost-effectiveness of the fixed-dose combination (FDC) of tiotropium + olodaterol Respimat ® FDC with tiotropium alone for patients with chronic obstructive pulmonary disease (COPD) in the ...
Carl Selya-Hammer, Nuria Gonzalez-Rojas Guix, Michael Baldwin, Andrew Ternouth, Marc Miravitlles, Maureen Rutten-van Mölken, Lucas M.A. Goosens, Nasuh Buyukkaramikli, Valentina Acciai   +8 more
doaj   +1 more source

Drugs Used in the Treatment of Viral Infections for the Prevention of Airway Remodeling in Asthma

Mediators of Inflammation, Volume 2025, Issue 1, 2025.
One of the main causes of the exacerbation of chronic airway inflammatory diseases is respiratory virus infections. The most prevalent viruses that can infect humans multiple times a year are rhinovirus (RV) and respiratory syncytial virus (RSV). Because remodeling factors like matrix metalloproteinases (MMPs), which are released by infiltrating ...
Joanna Wieczfinska, Rafal Pawliczak, Mirella Giovarelli   +2 more
wiley   +1 more source

Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease

International Journal of COPD, 2017
Chunxue Bai,1 Masakazu Ichinose,2 Sang Haak Lee,3 Kwan Ho Lee,4 Olaf Jöns,5 Ulrich Bothner,6 Yihua Zhao,7 Roland Buhl8 1Department of Pulmonary Medicine, Shanghai Respiratory Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China;
Bai C, Ichinose M, Lee SH, Lee KH, Jöns O, Bothner U, Zhao Y, Buhl R   +7 more
doaj